Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

The DILI-Inpt Prognostic Score to Identify Hospitalized Idiosyncratic DILI Patients at Risk for Adverse Outcomes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2025
Same author

Editorial: Cephalosporin-Induced Liver Injury-Interesting but Tricky. Authors' Reply.

Alimentary pharmacology & therapeutics·2025
Same author

Dapagliflozin-Associated Hepatotoxicity With a Positive Rechallenge.

ACG case reports journal·2025
Same author

Clinical and Genetic Associations in Cephalosporin-Induced Liver Injury: Insights From the Drug-Induced Liver Injury Network.

Alimentary pharmacology & therapeutics·2025
Same author

Right versus Middle Hepatic Vein access and One-Year TIPS Outcomes.

CVIR endovascular·2025

Related Experiment Video

Updated: Jul 4, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Acute liver failure including acetaminophen overdose.

Robert J Fontana1

  • 1Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical School, University of Michigan Medical Center, Ann Arbor, MI 48109-0362, USA. rfontana@med.umich.edu

The Medical Clinics of North America
|June 24, 2008
PubMed
Summary
This summary is machine-generated.

Acute liver failure (ALF) is a serious condition often caused by acetaminophen overdose. Early N-acetylcysteine treatment offers a 66% recovery chance, but prompt referral for liver transplantation is crucial for poor-prognosis patients.

More Related Videos

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

Related Experiment Videos

Last Updated: Jul 4, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration
05:37

Partial Lobular Hepatectomy: A Surgical Model for Morphologic Liver Regeneration

Published on: May 31, 2018

Area of Science:

  • Hepatology
  • Transplantation Medicine
  • Critical Care Medicine

Background:

  • Acute liver failure (ALF) is a sudden, unpredictable syndrome characterized by coagulopathy and encephalopathy.
  • Acetaminophen overdose is the primary cause of ALF in the United States.
  • Complications like cerebral edema and infections pose significant risks, potentially leading to multiorgan failure.

Purpose of the Study:

  • To summarize the clinical presentation and management of acute liver failure.
  • To highlight the efficacy of N-acetylcysteine in acetaminophen-induced ALF.
  • To emphasize the critical role of timely liver transplantation referral for patients with poor prognosis.

Main Methods:

  • Review of clinical data and outcomes for ALF patients.
  • Analysis of treatment effectiveness for N-acetylcysteine.
  • Evaluation of survival rates for liver transplantation.

Main Results:

  • Early N-acetylcysteine treatment and supportive care yield a 66% recovery rate in acetaminophen-induced ALF.
  • Liver transplantation offers a 70% one-year survival rate for eligible patients.
  • Twenty percent of patients listed for transplantation die before receiving an organ.

Conclusions:

  • Prompt N-acetylcysteine administration is vital for managing acetaminophen-induced ALF.
  • Early identification of ALF patients with poor prognosis and referral to transplant centers is essential for improving survival outcomes.
  • Multidisciplinary care is required to manage complex complications associated with ALF.